corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 15833

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: media release

Schmidt E.
UCLA leads nation in protecting med students from drug industry influence
UCLA Newsroom 2009 Jun 17
http://www.newsroom.ucla.edu/portal/ucla/ucla-leads-nation-in-protecting-94399.aspx


Full text:

The David Geffen School of Medicine at UCLA is one of only nine medical schools out of 149 to earn an ‘A’ grade in a nationwide survey by the American Medical Students Association of educational policies governing students’ contact with the pharmaceutical industry.

“We are proud to be in the top 6 percent of medical schools addressing this important issue,” said Dr. Andrew Leuchter, associate dean of the Geffen School of Medicine. “It is crucial that our nation’s physicians be trained to make decisions in the best interests of their patients, free of influence from private industry.”

UCLA was one of the first U.S. medical schools to adopt tough industry-relations guidelines. In November 2006, UCLA prohibited all industry gifts to faculty, staff and students; banned industry advertising materials and sales calls in patient care areas; and limited the use of drug samples to circumstances in the best interests of patients, such as cases of financial need.

In July 2007, UCLA’s guidelines were incorporated into the policy for the entire University of California system. In addition, UCLA now requires annual reporting by faculty members of all financial relationships with health care vendors.

Developed with the Pew Prescription Project, the 2009 scorecard (www.amsascorecard.org) evaluated each medical school’s policies in 11 areas, including restrictions on gifts, free meals and drug samples; paid promotional presentations; interaction with sales representatives; and industry-funded education. The results provide a school-by-school analysis of policies that govern the pharmaceutical industry’s interaction with faculty and students.

In addition to UCLA, top-ranked schools included Mount Sinai School of Medicine in New York; the University of Pittsburgh Medical Center; the University of Pennsylvania School of Medicine; the University of California, Davis, School of Medicine; the University of California, San Francisco, School of Medicine; the University of Texas Medical Branch at Galveston; Johns Hopkins School of Medicine; and the Mayo Medical School.

Pharmaceutical marketing to physicians has been estimated at up to $46 billion annually – roughly $35,000 per physician each year. These figures do not factor in promotion by the medical device industry. More than 100,000 pharmaceutical sales representatives visit U.S. doctors, often providing free lunches, gifts, drug samples and promotional medical literature.

The David Geffen School of Medicine tightly regulates interactions between private industry representatives and faculty, staff and students. For a detailed description of UCLA’s industry-relations policies, see http://dgsom.healthsciences.ucla.edu/administration/guidelinesMain.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.